CA2720141C - Beta-turn peptidomimetic cyclic compounds for treating dry eye - Google Patents

Beta-turn peptidomimetic cyclic compounds for treating dry eye Download PDF

Info

Publication number
CA2720141C
CA2720141C CA2720141A CA2720141A CA2720141C CA 2720141 C CA2720141 C CA 2720141C CA 2720141 A CA2720141 A CA 2720141A CA 2720141 A CA2720141 A CA 2720141A CA 2720141 C CA2720141 C CA 2720141C
Authority
CA
Canada
Prior art keywords
compound
day
scopolamine
dry eye
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2720141A
Other languages
English (en)
French (fr)
Other versions
CA2720141A1 (en
Inventor
Garth Cumberlidge
Karen Meerovitch
Teresa Lama
H. Uri Saragovi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mimetogen Pharmaceuticals Inc
Original Assignee
Mimetogen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mimetogen Pharmaceuticals Inc filed Critical Mimetogen Pharmaceuticals Inc
Publication of CA2720141A1 publication Critical patent/CA2720141A1/en
Application granted granted Critical
Publication of CA2720141C publication Critical patent/CA2720141C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/123—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2720141A 2008-04-04 2009-04-03 Beta-turn peptidomimetic cyclic compounds for treating dry eye Active CA2720141C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12303608P 2008-04-04 2008-04-04
US61/123,036 2008-04-04
US20887309P 2009-02-27 2009-02-27
US61/208,873 2009-02-27
PCT/US2009/002121 WO2009123761A1 (en) 2008-04-04 2009-04-03 Beta-turn peptidomimetic cyclic compounds for treating dry eye

Publications (2)

Publication Number Publication Date
CA2720141A1 CA2720141A1 (en) 2009-10-08
CA2720141C true CA2720141C (en) 2014-01-28

Family

ID=40897413

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2720141A Active CA2720141C (en) 2008-04-04 2009-04-03 Beta-turn peptidomimetic cyclic compounds for treating dry eye

Country Status (9)

Country Link
US (4) US8293713B2 (https=)
EP (1) EP2271337B1 (https=)
JP (2) JP5480242B2 (https=)
KR (1) KR101565185B1 (https=)
CN (1) CN102046166B (https=)
AU (1) AU2009232352B2 (https=)
CA (1) CA2720141C (https=)
ES (1) ES2521515T3 (https=)
WO (1) WO2009123761A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2521515T3 (es) * 2008-04-04 2014-11-12 Mimetogen Pharmaceuticals Inc. Compuestos cíclicos peptidomiméticos con giro beta para tratar el ojo seco
US9115179B2 (en) * 2012-06-22 2015-08-25 Mimetogen Pharmaceuticals Inc. Synthesis of beta-turn peptidomimetic cyclic compounds
KR20150004652A (ko) 2013-07-03 2015-01-13 삼성디스플레이 주식회사 표시 패널, 이를 포함하는 표시 장치 및 이를 이용하는 영상 표시 방법
JP6267003B2 (ja) * 2014-02-27 2018-01-24 参天製薬株式会社 ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
CN113230021A (zh) 2015-01-12 2021-08-10 科达莱昂治疗公司 微滴递送设备和方法
CN107530509A (zh) 2015-04-10 2018-01-02 科达莱昂治疗公司 具有可替换安瓿的压电分配器
AU2016290654C1 (en) * 2015-07-09 2021-11-11 Mimetogen Pharmaceuticals, Inc. Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts
KR101718733B1 (ko) 2015-08-21 2017-03-22 국제약품 주식회사 레바미피드의 가용화 방법 및 이에 의해 제조된 안구건조증 치료용 액제
WO2017152027A1 (en) 2016-03-04 2017-09-08 Rynerson James M Method of treating an eye disorder by inhibiting or disrupting bacterial biofilm formation
CN109906120A (zh) 2017-01-20 2019-06-18 科达莱昂治疗公司 压电流体分配器
WO2019113483A1 (en) 2017-12-08 2019-06-13 Kedalion Therapeutics, Inc. Fluid delivery alignment system
CN110092799B (zh) * 2018-01-29 2021-11-12 广州丹康医药生物有限公司 一种环状化合物、其制备方法和应用
US12350194B1 (en) 2018-04-12 2025-07-08 Bausch + Lomb Ireland Limited Topical ocular delivery of fluids with controlled mass dosing and wireless communication
US20190314197A1 (en) 2018-04-12 2019-10-17 Kedalion Therapeutics, Inc. Topical Ocular Delivery Methods and Devices for Use in the Same
WO2020010116A1 (en) 2018-07-03 2020-01-09 Kedalion Therapeutics, Inc. Topical ocular delivery devices and methods for using the same
US11679028B2 (en) 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
US12097145B2 (en) 2019-03-06 2024-09-24 Bausch + Lomb Ireland Limited Vented multi-dose ocular fluid delivery system
US12496218B1 (en) 2019-11-12 2025-12-16 Bausch + Lomb Ireland Limited Fractionated topical ocular drug delivery methods and devices for use in the same
US12290472B2 (en) 2020-04-17 2025-05-06 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
US11938057B2 (en) 2020-04-17 2024-03-26 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
EP4120973A4 (en) 2020-04-17 2024-04-17 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system having a collapsible liquid reservoir
CN115768384A (zh) 2020-04-17 2023-03-07 科达隆治疗公司 流体动力致动的不含防腐剂分配系统
WO2022256394A2 (en) * 2021-06-02 2022-12-08 The Texas A&M University System Selective small molecule agonists and partial agonists of trk receptors
WO2023069255A1 (en) * 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2023069549A1 (en) * 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8917217D0 (en) * 1989-07-27 1989-09-13 Smith & Nephew Ophthalmic compositions
US5545617A (en) 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
WO1999032135A1 (en) * 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
JP2001064198A (ja) 1999-08-24 2001-03-13 Teika Seiyaku Kk 角膜疾患治療剤
ATE340571T1 (de) * 2000-01-18 2006-10-15 Univ Mcgill Pharmazeutische zubereitungen enthaltend beta- turn peptidomimetische zyklische substanzen
EP1734052B1 (en) 2005-06-13 2009-02-18 Primm S.R.L. Heterodimeric peptide compounds displaying NGF activity and their use to treat neurodegenerative disorders
EP1921087A1 (en) 2006-11-10 2008-05-14 Primm S.R.L. Process for the preparation of cyclic peptides
JP5576659B2 (ja) * 2006-12-05 2014-08-20 ザ ロイヤル インスティテューション フォー ジ アドバンスメント オブ ラーニング／ マギル ユニバーシティ Ｔｒｋレセプター調節因子の使用方法
ES2521515T3 (es) * 2008-04-04 2014-11-12 Mimetogen Pharmaceuticals Inc. Compuestos cíclicos peptidomiméticos con giro beta para tratar el ojo seco
CA2752891C (en) * 2009-02-27 2018-08-21 Mimetogen Pharmaceuticals Inc. Peptidomimetic cyclic compounds for treating retinitis pigmentosa
US9115179B2 (en) * 2012-06-22 2015-08-25 Mimetogen Pharmaceuticals Inc. Synthesis of beta-turn peptidomimetic cyclic compounds

Also Published As

Publication number Publication date
CA2720141A1 (en) 2009-10-08
JP5480242B2 (ja) 2014-04-23
US8293713B2 (en) 2012-10-23
US9156882B2 (en) 2015-10-13
AU2009232352B2 (en) 2013-09-05
EP2271337B1 (en) 2014-09-03
US9707267B2 (en) 2017-07-18
EP2271337A1 (en) 2011-01-12
ES2521515T3 (es) 2014-11-12
US8748391B2 (en) 2014-06-10
CN102046166B (zh) 2012-10-17
US20120322747A1 (en) 2012-12-20
US20110105410A1 (en) 2011-05-05
KR101565185B1 (ko) 2015-11-02
KR20110010712A (ko) 2011-02-07
JP5870348B2 (ja) 2016-02-24
WO2009123761A1 (en) 2009-10-08
JP2011516477A (ja) 2011-05-26
HK1152898A1 (en) 2012-03-16
JP2014080447A (ja) 2014-05-08
CN102046166A (zh) 2011-05-04
AU2009232352A1 (en) 2009-10-08
US20140274910A1 (en) 2014-09-18
US20160082072A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
CA2720141C (en) Beta-turn peptidomimetic cyclic compounds for treating dry eye
KR100698449B1 (ko) 안구 혈관신생 질환 치료용 스타우로스포린 유도체의 용도
AU2010217889B2 (en) Peptidomimetic cyclic compounds for treating retinitis pigmentosa
US20240043396A1 (en) Methods of treating ocular fibrotic pathologies
HK1152898B (en) Beta-turn peptidomimetic cyclic compounds for treating dry eye
EP3284475A1 (en) Agent for prevention or treatment of corneal disorders
JP7749269B2 (ja) 新規のｄ－アミノ酸誘導体及びこれを含む薬学組成物
US20250161403A1 (en) Peptides and methods of use thereof in treating ocular disorders
US20250170143A1 (en) Methods of treating ocular fibrotic pathologies
CN118434434A (zh) 用于治疗、预防、抑制、改善眼科病状或延缓其发作的方法和包括肽模拟物的组合物
HK1161980A (en) Peptidomimetic cyclic compounds for treating retinitis pigmentosa
JPH1180000A (ja) 翼状片予防・治療剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130424

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20240801

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20241121

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241121

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250107

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250107

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250221

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250221

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250221

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260212

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260212